• Dr. Payami is the founder and Lead Investigator of the NeuroGenetics Research Consortium, a collaborative effort since 1992, formalized in 2004 as a Michael J Fox Foundation Global Genetics Consortium. Dr. Payami received her PhD in Genetics from UC Berkeley. She was a faculty member at the Oregon Health Sciences for 15 years, during which she developed independently-funded research program in Alzheimer and Parkinson genetics, won teaching awards for graduate and medical courses, and served as science faculty for the 9th Circuit and the Federal Judicial Education. She moved to New York in 2002, during which she served as the Director of the Genomics Institute at NY State Department of Health. In 2015 she was named the Juanelle D. Strain Endowed Chair in Neurology at the University of Alabama at Birmingham, where she continues her research, leads NGRC, and mentors students and young scientists. Her current research is focused on deciphering the interaction of human genome, gut microbiome and environmental factors in causation, progression and treatment of Parkinson's disease.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2022 Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms 2022
    2021 Exploring human-genome gut-microbiome interaction in Parkinson’s diseasenpj Parkinson's Disease.  7. 2021
    2021 Genomewide Association Studies of LRRK2 Modifiers of Parkinson's DiseaseAnnals of Neurology.  90:76-88. 2021
    2021 Large-scale association analyses identify host factors influencing human gut microbiome compositionNature Genetics.  53:156-165. 2021
    2020 Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogensnpj Parkinson's Disease.  6. 2020
    2020 Large-scale association analyses identify host factors influencing human gut microbiome composition 2020
    2020 Characterizing dysbiosis of gut microbiome in PD: evidence for overabundance of opportunistic pathogens.npj Parkinson's Disease.  6:11. 2020
    2020 Characterizing dysbiosis of gut microbiome in PD: Evidence for overabundance of opportunistic pathogens 2020
    2019 Using global team science to identify genetic parkinson's disease worldwideAnnals of Neurology.  86:153-157. 2019
    2018 Plasticity-related gene 3 (LPPR1) and age at diagnosis of Parkinson disease.Neurology Genetics.  4:e271. 2018
    2018 Meta-analysis of human genome-microbiome association studies: The MiBioGen consortium initiativeMicrobiome.  6. 2018
    2018 Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's DiseaseMovement Disorders.  33:793-804. 2018
    2018 Functional variants in the LRRK2 gene confer shared effects on risk for Crohn's disease and Parkinson's diseaseScience Translational Medicine.  10. 2018
    2017 The emerging science of precision medicine and pharmacogenomics for Parkinson's diseaseMovement Disorders.  32:1139-1146. 2017
    2017 Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiomeMovement Disorders.  32:739-749. 2017
    2017 Caffeine, creatine, GRIN2A and Parkinson's disease progressionJournal of the Neurological Sciences.  375:355-359. 2017
    2016 Identification of genetic modifiers of age-at-onset for familial Parkinson's diseaseHuman Molecular Genetics.  25:3849-3862. 2016
    2016 DNA variants in CACNA1C modify Parkinson disease risk only when Vitamin D level is deficientNeurology Genetics.  2. 2016
    2015 The relationship between obsessive-compulsive symptoms and PARKIN genotype: The CORE-PD studyMovement Disorders.  30:278-283. 2015
    2014 Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease.Neurology.  83:1906-1913. 2014
    2014 Erratum to "Exploratory analysis of seven Alzheimer's disease genes: Disease progression" [Neurobiol. Aging 34, (2013), 1310.e1-1310.e7], doi:10.1016/j.neurobiolaging.2012.08.014Neurobiology of Aging.  35:2661. 2014
    2014 Glutamate Receptor Gene GRIN2A, Coffee, and Parkinson DiseasePLoS Genetics.  10. 2014
    2014 Identification of a novel Parkinson's disease locus via stratified genome-wide association studyBMC Genomics.  15. 2014
    2014 Cognitive and motor function in long-duration PARKIN-associated parkinson diseaseJAMA Neurology.  71:62-67. 2014
    2014 Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's diseaseNature Genetics.  46:989-993. 2014
    2014 Promise of Pharmacogenomics for Drug Discovery, Treatment and Prevention of Parkinson's Disease. A PerspectiveNeurotherapeutics.  11:111-116. 2014
    2014 Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.Neurobiology of Aging.  35:266.e5-266.14. 2014
    2013 A genetic basis for the variable effect of smoking/nicotine on Parkinson's diseaseThe Pharmacogenomics Journal.  13:530-537. 2013
    2013 Association of parkinson disease with structural and regulatory variants in the hla regionAmerican Journal of Human Genetics.  93:984-993. 2013
    2013 Exploratory analysis of seven Alzheimer's disease genes: Disease progressionNeurobiology of Aging.  34:1310.e1-1310.e7. 2013
    2012 Cognitive performance of GBA mutation carriers with early-onset PD The CORE-PD studyNeurology.  78:1434-1440. 2012
    2012 Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDgene databasePLoS Genetics.  8. 2012
    2012 Meta-analysis of Parkinson's Disease: Identification of a novel locus, RIT2Annals of Neurology.  71:370-384. 2012
    2011 Evidence for more than one parkinson's Disease-Associated variant within the HLA regionPLoS One.  6. 2011
    2011 Disease-related and genetic correlates of psychotic symptoms in Parkinson's diseaseMovement Disorders.  26:2190-2195. 2011
    2011 An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's diseaseEuropean Journal of Neurology.  18. 2011
    2011 Genome-wide gene-environment study identifies glutamate receptor gene grin2a as a parkinson's disease modifier gene via interaction with coffeePLoS Genetics.  7. 2011
    2011 Postural instability/gait disturbance in Parkinson's disease has distinct subtypes: An exploratory analysisJournal of Neurology, Neurosurgery and Psychiatry.  82:564-568. 2011
    2010 SNCA variant associated with Parkinson disease and plasma α-synuclein levelArchives of Neurology.  67:1350-1356. 2010
    2010 Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's diseaseMovement Disorders.  25:2156-2163. 2010
    2010 A comprehensive analysis of deletions, multiplications, and copy number variations in PARK2Neurology.  75:1189-1194. 2010
    2010 The heritability of risk and age at onset of Parkinson's disease after accounting for known genetic risk factorsJournal of Human Genetics.  55:241-243. 2010
    2010 Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson’s diseaseNature Genetics.  42:781. 2010
    2010 Visualizing disease associations: Graphic analysis of frequency distributions as a function of age using moving average plots (MAP) with application to Alzheimer's and Parkinson's diseaseGenetic Epidemiology.  34:92-99. 2010
    2008 Genetic association between α-synuclein and idiopathic Parkinson's diseaseAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics.  147:1222-1230. 2008
    2008 Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.Lancet Neurology.  7:583-590. 2008
    2008 Exploring gene-environment interactions in Parkinson's diseaseHuman Genetics.  123:257-265. 2008
    2008 Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease riskMovement Disorders.  23:88-95. 2008
    2008 Lack of evidence for an association between UCHL1 S18Y and Parkinson's diseaseEuropean Journal of Neurology.  15:134-139. 2008
    2007 DBH -1021C→T does not modify risk or age at onset in Parkinson's diseaseAnnals of Neurology.  62:99-101. 2007
    2007 Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's diseaseAnnals of Neurology.  62:137-144. 2007
    2007 Heterozygous parkin point mutations are as common in control subjects as in Parkinson's patientsAnnals of Neurology.  61:47-54. 2007
    2007 Leucine-rich repeat kinase 1: A paralog of LRRK2 and a candidate gene for Parkinson's diseaseNeurogenetics.  8:95-102. 2007
    2006 Early-onset Alzheimer disease in families with late-onset alzheimer disease: A potential important subtype of familial Alzheimer diseaseArchives of Neurology.  63:1307-1311. 2006
    2006 Validity and utility of a LRRK2 G2019S mutation test for the diagnosis of Parkinson's diseaseGenetic Testing and Molecular Biomarkers.  10:221-227. 2006
    2006 Analysis of the LRRK2 G2019S mutation in Alzheimer disease [3]Archives of Neurology.  63:156-157. 2006
    2006 LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: Evidence of two distinct founding events beginning two millennia agoAmerican Journal of Human Genetics.  79:752-758. 2006
    2006 Lack of replication of thirteen single-nucleotide polymorphisms implicated in Parkinson's disease: a large-scale international studyLancet Neurology.  5:917-923. 2006
    2006 Parkinson's disease and LRRK2: Frequency of a common mutation in U.S. movement disorder clinicsMovement Disorders.  21:519-523. 2006
    2005 One step closer to fixing association studies: Evidence for age- and gender-specific allele frequency variations and deviations from Hardy-Weinberg expectations in controlsHuman Genetics.  118:322-330. 2005
    2005 Erratum: Parkin mutation analysis in clinic patients with early-onset Parkinson's disease (American Journal of Medical Genetics (2004) 129A (44-50) DOI: 10.1002/ajmg.a.30157)American Journal of Medical Genetics Part A.  139 A:56. 2005
    2005 Apolipoprotein E ε4 and catechol-O-methyltransferase alleles in autopsy-proven Parkinson's disease: Relationship to dementia and hallucinationsMovement Disorders.  20:989-994. 2005
    2005 Escaping Parkinson's disease: A neurologically healthy octogenarian with the LRRK2 G2019S mutation [2]Movement Disorders.  20:1077-1078. 2005
    2005 False-positive SCA8 gene test in a patient with pathologically proven multiple system atrophy [1]Annals of Neurology.  57:462-463. 2005
    2005 parkin mutation dosage and the phenomenon of anticipation: A molecular genetic study of familial parkinsonismBMC Neurology.  5. 2005
    2005 Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: Evidence of a common founder across European populationsAmerican Journal of Human Genetics.  76:672-680. 2005
    2004 parkin mutation analysis in clinic patients with early-onset Parkinson [corrected] disease.American Journal of Medical Genetics Part A.  129A:44-50. 2004
    2004 parkin mutation analysis in clinic patients with early-onset Parkinson's diseaseAmerican Journal of Medical Genetics Part A.  129 A:44-50. 2004
    2004 Evidence of linkage and association on chromosome 20 for late-onset Alzheimer diseaseNeurogenetics.  5:121-128. 2004
    2004 Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2)Movement Disorders.  19:622-629. 2004
    2004 Evidence for a novel late-onset Alzheimer disease locus on chromosome 19p13.2American Journal of Human Genetics.  75:398-409. 2004
    2003 Independent predictors of cognitive decline in the healthy elderlyResearch and practice in Alzheimer's disease.  7:86-92. 2003
    2003 A linkage study of candidate loci in familial Parkinson's DiseaseBMC Neurology.  3. 2003
    2003 SCA2 may present as levodopa-responsive parkinsonismMovement Disorders.  18:425-429. 2003
    2002 Onset age of Parkinson disease [9] (multiple letters)American Journal of Medical Genetics Part A.  111:459-460. 2002
    2002 Familial aggregation of Parkinson disease: A comparative study of early-onset and late-onset diseaseArchives of Neurology.  59:848-850. 2002
    2002 HLA-A2 homozygosity but not heterozygosity is associated with Alzheimer diseaseNeurology.  58:973-975. 2002
    2002 Age at onset of Parkinson disease and apolipoprotein E genotypesAmerican Journal of Medical Genetics Part A.  107:156-161. 2002
    2002 Accurate determination of ataxin-2 polyglutamine expansion in patients with intermediate-range repeatsGenetic Testing and Molecular Biomarkers.  6:217-220. 2002
    2002 Independent predictors of cognitive decline in healthy elderly personsArchives of Neurology.  59:601-606. 2002
    2001 Expression of α-synuclein in the human brain: Relation to Lewy body diseaseBrain Research.  92:58-65. 2001
    2001 Parkinson's disease, CYP2D6 polymorphism, and ageNeurology.  56:1363-1370. 2001
    2001 Frequency of tau gene mutations in familial and sporadic cases of non-Alzheimer dementiaArchives of Neurology.  58:383-387. 2001
    2001 Predictors of healthy brain agingJournal of Gerontology Series A: Biological Sciences and Medical Sciences.  56:B294-B301. 2001
    2000 The number of trait loci in late-onset Alzheimer diseaseAmerican Journal of Human Genetics.  66:196-204. 2000
    1999 Apolipoprotein E ε4 is associated with neuronal loss in the substantia nigra in Alzheimer's diseaseDementia and Geriatric Cognitive Disorders.  10:437-441. 1999
    1999 Exclusion of dominant mutations within the FTDP-17 locus on chromosome 17 for Parkinson's diseaseNeuroscience Letters.  272:140-142. 1999
    1999 A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L)Brain: a journal of neurology.  122:741-756. 1999
    1999 Apolipoprotein E genotype does not affect the age of onset of dementia in families with defined tau mutationsNeuroscience Letters.  260:193-195. 1999
    1999 Correction: A clinical pathological comparison of three families with frontotemporal dementia and identical mutations in the tau gene (P301L) (Brain (1999) 122, 4 (741-756))Brain: a journal of neurology.  122:1398. 1999
    1998 Segregation analysis of Parkinson diseaseAmerican Journal of Medical Genetics Part A.  80:410-417. 1998
    1998 Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17Proceedings of the National Academy of Sciences of USA.  95:13103-13107. 1998
    1998 Analysis of the α-synuclein G209A mutation in familial Parkinson's disease [7]The Lancet.  351:37-38. 1998
    1998 Apolipoprotein E genotypes and age at onset of Parkinson's disease [4] (multiple letters)Annals of Neurology.  44:294-295. 1998
    1998 Genetic epidemiology of Parkinson's diseaseJournal of Geriatric Psychiatry and Neurology.  11:98-106. 1998
    1997 Modulation of the age at onset of Parkinson's disease by apolipoprotein E genotypesAnnals of Neurology.  42:655-658. 1997
    1997 A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): Effects of family history and apolipoprotein E genotypeAmerican Journal of Human Genetics.  60:948-956. 1997
    1997 Chromosome 17 and hereditary dementia: Linkage studies in three non- Alzheimer families and kindreds with late-onset FADNeurology.  48:949-954. 1997
    1997 Cognitive markers preceding Alzheimer's dementia in the healthy oldest oldJournal of the American Geriatrics Society.  45:584-589. 1997
    1997 Evidence for association of HLA-A2 allele with onset age of Alzheimer's diseaseNeurology.  49:512-518. 1997
    1996 Gender difference in apolipoprotein E - associated risk for familial alzheimer disease: A possible clue to the higher incidence of alzheimer disease in womenAmerican Journal of Human Genetics.  58:803-811. 1996
    1996 Increased risk of familial late-onset Alzheimer's disease in womenNeurology.  46:126-129. 1996
    1996 Reply from the Author: Gender and ADNeurology.  47:1358. 1996
    1995 The Apolipoprotein E E4 Allele and Sex-Specific Risk of Alzheimer's Disease-ReplyJAMA: Journal of the American Medical Association.  273:374. 1995
    1995 Genetic anticipation in parkinson's diseaseNeurology.  45:135-138. 1995
    1995 Increased Risk of Parkinson's Disease in Relatives of PatientsAnnals of Neurology.  37:685-685. 1995
    1995 No evidence for association of familial parkinson's disease with cag repeat expansionNeurology.  45:1760-1763. 1995
    1995 ReplyAnnals of Neurology.  37:685-685. 1995
    1994 Alzheimer's Disease, Apolipoprotein E4, and GenderJAMA: Journal of the American Medical Association.  271:1316-1317. 1994
    1994 Alzheimer's disease, apolipoprotein E4, and genderJAMA: Journal of the American Medical Association.  271:1316-1317. 1994
    1994 Evidence for familial factors that protect against dementia and outweigh the effect of increasing ageAmerican Journal of Human Genetics.  54:650-657. 1994
    1994 The apolipoprotein E/CI/CII gene cluster and late-onset Alzheimer diseaseAmerican Journal of Human Genetics.  54:631-642. 1994
    1994 Genetic factors that protect against dementia [6]American Journal of Human Genetics.  55:588-589. 1994
    1994 Increased risk of Parkinson's disease in parents and siblings of patientsAnnals of Neurology.  36:659-661. 1994
    1993 Apolipoprotein E genotype and Alzheimer's diseaseThe Lancet.  342:737-738. 1993
    1993 Apolipoprotein E genotype and Alzheimer's disease.The Lancet.  342:738. 1993
    1993 Chromosome 14 and late-onset familial Alzheimer disease (FAD)American Journal of Human Genetics.  53:619-628. 1993
    1993 Lack of evidence for maternal effect in familial Alzheimer's diseaseGenetic Epidemiology.  10:461-464. 1993
    1992 Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene regionAmerican Journal of Human Genetics.  51:998-1014. 1992
    1991 HLA-A2, or a closely linked gene, confers susceptibility to early-onset sporadic alzheimer’s disease in meneNeurology.  41:1544-1548. 1991
    1989 Disease associations and disequilibrium mapping.Progress in clinical and biological research.  329:57-62. 1989
    1989 A simple method to detect and estimate heterogeneity: application to Huntington disease, diabetes, and HIV seroconversionAmerican Journal of Human Genetics.  44:107-114. 1989
    1989 Autoimmune thyroid disease in type I diabetic familiesGenetic Epidemiology.  6:137-141. 1989
    1989 HLA may be involved in resistance and susceptibility to affective disordersGenetic Epidemiology.  6:293-298. 1989
    1989 Relative predispositional effects (RPEs) of marker alleles with disease: HLA-DR alleles and Graves diseaseAmerican Journal of Human Genetics.  45:541-546. 1989
    1987 Analysis of genetic interrelationship among HLA-associated diseasesAmerican Journal of Human Genetics.  41:331-349. 1987
    1987 The affected sib method. V. Testing the assumptionsAnnals of Human Genetics.  51:75-92. 1987
    1987 The affected sib method. V. Testing the assumptions.Annals of Human Genetics.  51:75-92. 1987
    1986 A synergistic three allele model for the HLA‐linked components of coeliac disease predispositionGenetic Epidemiology.  3:277-282. 1986
    1986 Family and population analysis of multiple sclerosisGenetic Epidemiology.  3:381-386. 1986
    1986 Genetics of rheumatoid arthritisTissue Antigens: immune response genetics.  27:57-63. 1986
    1985 The affected sib method. IV. Sib trios.Annals of Human Genetics.  49:303-314. 1985
    1985 The affected sib method. IV. Sib triosAnnals of Human Genetics.  49:303-314. 1985
    1984 The affected sib method. III. Selection and recombination.American Journal of Human Genetics.  36:352-362. 1984
    1984 The affected sib method. III. Selection and recombinationAmerican Journal of Human Genetics.  36:353-362. 1984
    1983 The affected sib method. II. The intermediate model.Annals of Human Genetics.  47:225-243. 1983
    1983 The affected sib method. II. The intermediate modelAnnals of Human Genetics.  47:225-243. 1983


    Year Title Altmetric
    2008 Reaching a Diagnosis of a Dementia Subtype.  106-193. 2008

    Education And Training

  • Doctor of Philosophy in Genetics, University of California System : Berkeley 1985
  • Full Name

  • Haydeh Payami